SR ONE CAPITAL MANAGEMENT, LLC
Reporting owner on Forms 3, 4 and 5, CIK 1853723.
- In the filer group SR ONE CAPITAL MANAGEMENT, LLC
SR ONE CAPITAL MANAGEMENT, LLC reported on 1 issuer in 2 filings, the latest a 13D filed 2026-10-05.
Issuers
| Issuer | Roles in the latest filing | Filings | Last filed |
|---|---|---|---|
| ADARx Pharmaceuticals, Inc. CIK 1802369 | 10% owner | 1 | 2026-09-29 |
Transactions and holdings
Every row of the person's Forms 3, 4 and 5, newest first, with the price and the amount owned after the row as filed.
| Security | Date | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| ADARx Pharmaceuticals, Inc. Common Stock | 2026-09-28 | C converted | +3,334,938 | 3,334,938 | Form 4 | |
| ADARx Pharmaceuticals, Inc. Common Stock | 2026-09-28 | C converted | +1,113,666 | 4,448,604 | Form 4 | |
| ADARx Pharmaceuticals, Inc. Common Stock | 2026-09-28 | C converted | +512,897 | 4,961,501 | Form 4 | |
| ADARx Pharmaceuticals, Inc. Common Stock | 2026-09-28 | P bought | +592,593 | $17 | 5,554,094 | Form 4 |
| ADARx Pharmaceuticals, Inc. Common Stock | 2026-09-28 | C converted | +1,538,691 | 1,538,691 | Form 4 | |
| ADARx Pharmaceuticals, Inc. Common Stock | 2026-09-28 | P bought | +414,814 | $17 | 1,953,505 | Form 4 |
| ADARx Pharmaceuticals, Inc. Common Stock | 2026-09-28 | C converted | +1,667,468 | 1,667,468 | Form 4 | |
| ADARx Pharmaceuticals, Inc. Common Stock | 2026-09-28 | C converted | +169,001 | 1,836,469 | Form 4 | |
| ADARx Pharmaceuticals, Inc. Common Stock | 2026-09-28 | P bought | +592,593 | $17 | 592,593 | Form 4 |
| ADARx Pharmaceuticals, Inc. Series B Preferred Stock, derivative | 2026-09-28 | C converted | -3,907,547 | $0 | 0 | Form 4 |
| ADARx Pharmaceuticals, Inc. Series B-1 Preferred Stock, derivative | 2026-09-28 | C converted | -1,304,883 | $0 | 0 | Form 4 |
| ADARx Pharmaceuticals, Inc. Series C Preferred Stock, derivative | 2026-09-28 | C converted | -600,962 | $0 | 0 | Form 4 |
| ADARx Pharmaceuticals, Inc. Series C Preferred Stock, derivative | 2026-09-28 | C converted | -1,802,885 | $0 | 0 | Form 4 |
| ADARx Pharmaceuticals, Inc. Series B Preferred Stock, derivative | 2026-09-28 | C converted | -1,953,773 | $0 | 0 | Form 4 |
| ADARx Pharmaceuticals, Inc. Series B-1 Preferred Stock, derivative | 2026-09-28 | C converted | -198,019 | $0 | 0 | Form 4 |
Filings
The person's Forms 3, 4 and 5, and any 13D or 13G naming it.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13D 0001072613-26-000820 | ADARX PHARMACEUTICALS INC | 2026-10-05 | ||
| Form 4 0001193125-26-408064 | ADARx Pharmaceuticals, Inc. | 2026-09-29 |